Cargando…

Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies

Latent human cytomegalovirus (HCMV) infection is characterized by limited gene expression, making latent HCMV infections refractory to current treatments targeting viral replication. However, reactivation of latent HCMV in immunosuppressed solid organ and stem cell transplant patients often results...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Groof, Timo W. M., Elder, Elizabeth G., Lim, Eleanor Y., Heukers, Raimond, Bergkamp, Nick D., Groves, Ian J., Wills, Mark, Sinclair, John H., Smit, Martine J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295288/ https://www.ncbi.nlm.nih.gov/pubmed/34290252 http://dx.doi.org/10.1038/s41467-021-24608-5

Ejemplares similares

Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells
por: De Groof, Timo W. M., et al.
Publicado: (2019)

Monocytes Latently Infected with Human Cytomegalovirus Evade Neutrophil Killing
por: Elder, Elizabeth, et al.
Publicado: (2019)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein
por: Krishna, B. A., et al.
Publicado: (2017)

Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells
por: Comez, Dehan, et al.
Publicado: (2022)

Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells
por: Krishna, B. A., et al.
Publicado: (2016)

Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies
por: De Groof, Timo W. M., et al.
Publicado: (2021)

HCMV Antivirals and Strategies to Target the Latent Reservoir
por: Perera, Marianne R., et al.
Publicado: (2021)

Latency-Associated Expression of Human Cytomegalovirus US28 Attenuates Cell Signaling Pathways To Maintain Latent Infection
por: Krishna, Benjamin A., et al.
Publicado: (2017)

Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates
por: Wakileh, Gamal A., et al.
Publicado: (2023)

Latent Cytomegalovirus-Driven Recruitment of Activated CD4+ T Cells Promotes Virus Reactivation
por: Jackson, Sarah E., et al.
Publicado: (2021)

Cytomegalovirus establishes a latent reservoir and triggers long-lasting inflammation in the eye
por: Voigt, Valentina, et al.
Publicado: (2018)

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor
por: Van Campenhout, Raf, et al.
Publicado: (2021)

Human Cytomegalovirus Manipulation of Latently Infected Cells
por: Sinclair, John H., et al.
Publicado: (2013)

Interferon-Responsive Genes Are Targeted during the Establishment of Human Cytomegalovirus Latency
por: Elder, Elizabeth G., et al.
Publicado: (2019)

Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury
por: Van Campenhout, Raf, et al.
Publicado: (2023)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs
por: Kuang, Xiaomei T., et al.
Publicado: (2018)

Advances in the treatment of cytomegalovirus
por: Krishna, B A, et al.
Publicado: (2019)

Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells
por: Jackson, Sarah E., et al.
Publicado: (2017)

Human Cytomegalovirus-Encoded G Protein-Coupled Receptor UL33 Facilitates Virus Dissemination via the Extracellular and Cell-to-Cell Route
por: van Senten, Jeffrey R., et al.
Publicado: (2020)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

The Human Cytomegalovirus Latency-Associated Gene Product Latency Unique Natural Antigen Regulates Latent Gene Expression
por: Poole, Emma, et al.
Publicado: (2023)

The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022)

Human cytomegalovirus major immediate early transcripts arise predominantly from the canonical major immediate early promoter in reactivating progenitor-derived dendritic cells
por: Mason, Rebecca, et al.
Publicado: (2020)

Generation, maintenance and tissue distribution of T cell responses to human cytomegalovirus in lytic and latent infection
por: Jackson, Sarah E., et al.
Publicado: (2019)

The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People
por: Lim, Eleanor Y., et al.
Publicado: (2020)

Human Cytomegalovirus Upregulates Expression of HCLS1 Resulting in Increased Cell Motility and Transendothelial Migration during Latency
por: Aslam, Yusuf, et al.
Publicado: (2019)

Heterogeneity of HIV-1 latent reservoirs
por: Zhao, Jia-Cong, et al.
Publicado: (2020)

A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells
por: Poole, Emma, et al.
Publicado: (2021)

Control of Cytokines in Latent Cytomegalovirus Infection
por: Chinta, Pearley, et al.
Publicado: (2020)

The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6
por: Lau, Betty, et al.
Publicado: (2016)

Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention
por: Groves, Ian J., et al.
Publicado: (2021)

Corrigendum: The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6
por: Lau, Betty, et al.
Publicado: (2016)

A scalable workflow to test “shock and kill” therapeutic approaches against the HIV-1 latent reservoir in blood cells ex vivo
por: Procopio, Francesco Andrea, et al.
Publicado: (2023)

A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir
por: Fun, Axel, et al.
Publicado: (2017)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

How to Define the Latent Reservoir: Tools of the Trade
por: Barton, Kirston M., et al.
Publicado: (2016)

HIV-1 latent reservoir: size matters
por: Hodel, Flavia, et al.
Publicado: (2016)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vprpcstj8kjokkpsf7v6m41pqr